ECDC Expert consultation on community engagement in public health emergency preparedness
The expert consultation meeting organised by ECDC seeks to identify enabling factors and barriers to good practice in community engagement in the context of public health emergency preparedness. Outcomes of this meeting will inform the development of an ECDC guidance on the topic.
ECDC’s HEPSA preparedness self-assessment tool is now available in all EU/EEA languages
The HEPSA (Health Emergency Preparedness Self-Assessment) tool that ECDC launched in 2018 in English is now available in all EU/EEA languages. This tool aims at supporting countries in improving their level of public health emergency preparedness.
Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?
Vourli, G., Pharris, A., Cazein, F., Costagliola, D., Dabis, F., Del Amo, J., Delpech, V., Diaz, E., Girardi, A., Gourlay, A., Gunsenheimer-Bartmeyer, B., Hernando, V., Nikolopoulos, G., Porter, K., Rosinska, M., Sabin, C., Suligoi, B. Supervie, V., Wit, F., Touloumi, G.
HIV in Europe and Central Asia: progress in 2018 towards meeting the UNAIDS 90-90-90 targets
Brown, A.E., Hayes, R., Noori, T., Azad, Y., Amato-Gauci, A.J., Pharris, A., Delpech, V.C., The Ecdc Dublin Declaration Monitoring Network
Lymphogranuloma venereum (LGV) in men who have sex with men (MSM): A re-emerging problem, Malta, 2018
Donachie, A., Spiteri, G., Barbara, C., Melillo, T., Hadad, R., Farrugia, A.G., Unemo, M., Padovese, V.
HEPSA – health emergency preparedness self-assessment tool, User guide
HEPSA is used to evaluate levels of preparedness, identify potential gaps, identify vulnerabilities, and detect areas for improvement – with the goal to strengthen overall preparedness capacities for public health emergencies. This user guide provides basic information on the self-assessment process.
Potential adjustment methodology for missing data and reporting delay in the HIV surveillance system, European Union/European Economic Area, 2015
Rosinska, M., Pantazis, N., Janiec, J., Pharris, A., Amato-Gauci, A.J., Quinten, C., Schmid, D., Sasse, A., van Beckhoven, D., Varleva, T., Blazic, T.N., Hadjihannas, L., Koliou, M., Maly, M., Cowan, S., Rüütel, K., Liitsola, K., Salminen, M., Cazein, F., Pillonel, J., Lot, F., Gunsenheimer-Bartmeyer, B., Nikolopoulos, G., Paraskeva, D., Dudas, M., Briem, H., Sigmundsdottir, G., Igoe, D., O’Donnell, K., O’Flanagan, D., Suligoi, B., Konova, Š., Erne, S., Čaplinskienė, I., Schmit, A.F.J.-C., Melillo, J.M., Melillo, T., de Coul, E.O., van Sighem, A., Blystad, H., Rosinska, M., Aldir, I., Martins, H.C., Mardarescu, M., Truska, P., Klavs, I., Diaz, A., Axelsson, M., Delpech, V.
ECDC: first detected cases of extensively drug-resistant gonorrhoea threaten future treatment
Within a matter of weeks, three cases of gonorrhoea that are resistant to the recommended first line antibiotic treatment have been detected in Europe and Australia. These are the first global reports of Neisseria gonorrhoeae with high-level resistance to azithromycin and ceftriaxone resistance that also show resistance to several other vital antibiotics. At a time with limited alternatives to the current dual therapy, lack of a vaccine and insufficient surveillance capacity in some regions, these cases highlight the growing threat of drug-resistance – which could lead to untreatable gonorrhoea.